<DOC>
	<DOCNO>NCT01501383</DOCNO>
	<brief_summary>The purpose study evaluate efficacy , safety tolerability VX-765 subject treatment-resistant partial epilepsy .</brief_summary>
	<brief_title>A Study Evaluate Efficacy Safety VX-765 Subjects With Treatment-Resistant Partial Epilepsy</brief_title>
	<detailed_description />
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Epilepsies , Partial</mesh_term>
	<criteria>Part A Part B Males female age 18 64 year body mass index 18 35 ( kg/m2 ) Subjects complete assigned study treatment Part A may enter Part B eligible per protocol Male female subject must agree use acceptable contraceptive method , describe protocol Must diagnosis history treatmentresistant partialonset epilepsy take 1 4 concomitant AEDs time Screening Period Have least 1 electroencephalogram consistent partial epilepsy Must least 6 partialonset seizure seizurefree period 3 week ( 21 day ) Baseline Period . Subjects stable medical condition ( e.g. , condition interfere conduct study cause know increase risk intervention ) determine principal investigator Must able willing provide write informed consent participate Must able understand comply protocol requirement instruction Part A Part B Subjects male female partner ( childbearing potential ) agree use medically approve method contraception describe protocol duration od study 90 day last dose study drug Subjects male female partner pregnant , nursing , plan become pregnant study period , within 90 day last dose study drug . Subjects pregnant lactating , reproductive potential agree use medically approve birth control method History nonepileptic , transient alteration consciousness History status epilepticus past 12 month screen visit Subjects whose seizure frequency quantify ( i.e . seizures discrete begin end , period seizure ) Subjects significant medical illness include kidney , liver , pulmonary , gastrointestinal disease ; unstable poorly control condition hypertension , diabetes , angina pectoris , judge investigator . Have clinically significant psychiatric illness judge investigator Subjects active suicidal plan/intent active suicidal thought , suicide attempt define protocol Clinically significant laboratory abnormality Screening Visit/Baseline Period , judge investigator Subjects serious adverse event ( SAEs ) think related study drug lead discontinuation Part A may participate Part B Active hepatitis B , hepatitis C , human immunodeficiency virus Positive drug screen screen Baseline Period ( exclude allow prescribed medication ) and/or history alcoholism drug addiction within past 2 year Subjects felbamate few 18 month continuous felbamate exposure time Screening Visit significant adverse reaction felbamate Subjects treat vigabatrin few 2 year prior Screening Visit prior history treatment vigabatrin without document stable examination ophthalmologist define protocol Using prohibit medication treat systemic immunosuppressant Have experience symptomatic viral , fungal , bacterial infection require systemic treatment within 7 day prior first dose study drug A current prior history illness preclude immunomodulatory therapy ( e.g. , history recurrent infection ) Have donate blood significant loss blood ( 500 mL ) define protocol Have participate clinical study involve investigational product device receive last dose study drug associate clinical study within 30 day 5 halflives ( whichever longer ) Screening Visit Have participate earlier VX765 clinical study receive least one dose study drug Subjects complete full 13week Treatment Period part A may participate Part B Any subject judge investigator , sponsor designee inappropriate study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>October 2012</verification_date>
</DOC>